The stock price of Anavex Life Sciences Corporation (NASDAQ: AVXL) has surged by 14.74 when compared to previous closing price of 7.60, but the company has seen a 1.87% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-05 that ATTENTION-AD trial data through 192 weeks presented at AD/PD TM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer’s disease Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX®2-73) demonstrated significantly amelioration on clinical decline showing continued clinically and meaningful benefit for early Alzheimer’s disease patients. ATTENTION-AD (ANAVEX®2-73-AD-EP-004) trial result was presented at the AD/PDTM 2025 Conference.
Is It Worth Investing in Anavex Life Sciences Corporation (NASDAQ: AVXL) Right Now?
Moreover, the 36-month beta value for AVXL is 0.88. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AVXL is 82.26M and currently, short sellers hold a 29.23% of that float. On April 10, 2025, AVXL’s average trading volume was 1.22M shares.
AVXL’s Market Performance
AVXL stock saw a decrease of 1.87% in the past week, with a monthly decline of -2.90% and a quarterly a decrease of -35.22%. The volatility ratio for the week is 12.62%, and the volatility levels for the last 30 days are 8.11% for Anavex Life Sciences Corporation (AVXL). The simple moving average for the past 20 days is -2.86% for AVXL’s stock, with a 15.78% simple moving average for the past 200 days.
Analysts’ Opinion of AVXL
Many brokerage firms have already submitted their reports for AVXL stocks, with Cantor Fitzgerald repeating the rating for AVXL by listing it as a “Neutral.” The predicted price for AVXL in the upcoming period, according to Cantor Fitzgerald is $11 based on the research report published on December 06, 2022 of the previous year 2022.
Berenberg, on the other hand, stated in their research note that they expect to see AVXL reach a price target of $40. The rating they have provided for AVXL stocks is “Buy” according to the report published on June 23rd, 2022.
BTIG Research gave a rating of “Buy” to AVXL, setting the target price at $35 in the report published on September 23rd of the previous year.
AVXL Trading at -0.59% from the 50-Day Moving Average
After a stumble in the market that brought AVXL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.61% of loss for the given period.
Volatility was left at 8.11%, however, over the last 30 days, the volatility rate increased by 12.62%, as shares sank -2.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.01% lower at present.
During the last 5 trading sessions, AVXL rose by +1.87%, which changed the moving average for the period of 200-days by +113.73% in comparison to the 20-day moving average, which settled at $8.98. In addition, Anavex Life Sciences Corporation saw -18.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVXL starting from Donhauser Peter D.O., who purchase 2,835 shares at the price of $3.64 back on Jun 14 ’24. After this action, Donhauser Peter D.O. now owns 5,000 shares of Anavex Life Sciences Corporation, valued at $10,319 using the latest closing price.
Thomas Steffen, the Director of Anavex Life Sciences Corporation, purchase 5,000 shares at $4.52 during a trade that took place back on May 15 ’24, which means that Thomas Steffen is holding 5,000 shares at $22,600 based on the most recent closing price.
Stock Fundamentals for AVXL
The total capital return value is set at -0.5. Equity return is now at value -37.72, with -34.17 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 9.45.
Conclusion
To wrap up, the performance of Anavex Life Sciences Corporation (AVXL) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
